Sequential Therapy (NRX-100 Followed by NRX-101) for the Treatment of Acute Suicidal Ideation and Behavior in Bipolar Depression: the STABIL-B Study

Next Previous
Trial Profile

Sequential Therapy (NRX-100 Followed by NRX-101) for the Treatment of Acute Suicidal Ideation and Behavior in Bipolar Depression: the STABIL-B Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs Cycloserine/lurasidone (Primary) ; Ketamine; Lurasidone
  • Indications Bipolar depression; Suicidal ideation
  • Focus Registrational; Therapeutic Use
  • Acronyms STABIL-B
  • Sponsors NeuroRX

    • Most Recent Events

    • 06 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 05 Jan 2018 Planned initiation date changed from 15 Jun 2017 to 15 Jan 2018.
    • 06 Sep 2017 According to a NeuroRX media release, the company will shortly begin enrolling patients in a pivotal trial of this sequential therapy targeting patients who are admitted to Emergency Departments with ASIB in bipolar depression.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top